What would allow Viking Therapeutics to match Wall Street’s average price target, or at least get close to it? The biotech company will need to post strong phase 3 results for VK2735. Note that, since …
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street
view original post